315 related articles for article (PubMed ID: 36505492)
21. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
Nagata N; Kagawa T; Hirose S; Arase Y; Tsuruya K; Anzai K; Shiraishi K; Mine T
BMC Gastroenterol; 2016 Mar; 16():38. PubMed ID: 26987437
[TBL] [Abstract][Full Text] [Related]
22. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations].
Martín Mateos RM; Moreira Vicente VF; Tavío Hernández E; Cuño Roldán JL; Téllez Villajos L; Aicart Ramos M; Arribas Anta J; Zaera de la Fuente C; Albillos Martínez A
Gastroenterol Hepatol; 2015 May; 38(5):305-12. PubMed ID: 25636371
[TBL] [Abstract][Full Text] [Related]
23. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
[TBL] [Abstract][Full Text] [Related]
24. Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.
Chen YC; Hsu CW; Chien RN
J Med Virol; 2023 Nov; 95(11):e29213. PubMed ID: 37933418
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
26. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B.
Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
Korean J Gastroenterol; 2016 Jan; 67(1):28-34. PubMed ID: 26809629
[TBL] [Abstract][Full Text] [Related]
27. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
[TBL] [Abstract][Full Text] [Related]
28. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
[TBL] [Abstract][Full Text] [Related]
29. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
[TBL] [Abstract][Full Text] [Related]
30. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
31. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
Yu SL; Guo CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
[TBL] [Abstract][Full Text] [Related]
32. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
[TBL] [Abstract][Full Text] [Related]
33. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
Song MJ; Song DS; Kim HY; Yoo SH; Bae SH; Choi JY; Yoon SK; Paik YH; Lee JS; Lee HW; Kim HJ
World J Gastroenterol; 2012 Nov; 18(43):6277-83. PubMed ID: 23180949
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of clinical characteristics of persistent HBeAg positivity in patients with chronic hepatitis B treated with nucleos(t)ide analogues].
Peng LP; Gan WQ; Zheng YB; Chen YM; Liu J; Wu ZB; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2024 Mar; 32(3):193-200. PubMed ID: 38584099
[No Abstract] [Full Text] [Related]
35. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
[TBL] [Abstract][Full Text] [Related]
36. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
38. When can we stop nucleoside analogues in patients with chronic hepatitis B?
Chong CH; Lim SG
Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
[TBL] [Abstract][Full Text] [Related]
39. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.
Lu J; Li J; Liu Y; Ren S; Cao Z; Jin Y; Ma L; Shen C; Chen X
PLoS One; 2015; 10(11):e0141072. PubMed ID: 26524467
[TBL] [Abstract][Full Text] [Related]
40. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B.
Lee SK; Kwon JH; Lee SW; Jang JW; Nam H; Baik KW; Yoo SH; Nam SW; Sung PS; Bae SH; Choi JY; Yoon SK
Liver Int; 2021 Feb; 41(2):288-294. PubMed ID: 33043567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]